Long-term survival and cost of treatment in patients with stage IIIC epithelial ovarian cancer

Current Women's Health Reviews

Volumn 5, Issue 1, 2009, Pages 44-50

  Cooper, Amy L ^a   Nelson, David F ^a   Doran, Stacy ^a   Ueland, Fred R ^a   DeSimone, Christopher P ^a   DePriest, Paul D ^a   McDonald, John M ^a   Saunders, Brook A ^a   Ware, Rachel A ^a   Pavlik, Edward J ^a   Kryscio, Richard J ^a   Karpf, Michael ^a   van Nagell Jr , John R ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Cost of treatment; Ovarian carcinoma; Surgery; Survival

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITAL BILLING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL FEE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 65949098677     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340409787721294     Document Type: Review

References (20)

1. Goff BA, Mandel L, Drescher CW, et al. Development of an ovarian cancer symptom index. Cancer 2007; 109: 221-227.
2. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291: 2705-2712.
3. Smith LH. Early clinical detection of ovarian cancer: a review of the evidence. Expert Rev Anticancer Ther 2006; 6: 1045-1052.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57: 43-66.
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era. A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
6. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200.
7. Rustin GJ, Quinn M, Thigpen T, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96: 487-488.
8. Rustin GJ. Use of Ca-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21: 187-193.
9. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992; 10: 513-514.
10. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytroreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008; 108: 276-281.
11. http://oregonstate.edu/cla/polisci/faculty-research/sahr/sahr.htm Confirmed available 6/4/2008.
12. Redbook: Pharmacy's Fundamental Reference. R. ANEX Medica Publisher. Los Angeles, CA, 2007.
13. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006; 103: 1083-1090.
14. Eisenkop SM, Spirtos NM, Montag TW, Montag TW, Nalick RH, Wange HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992; 47: 203-209.
15. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733.
16. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-3352.
17. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-3100.
18. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 130-135.
19. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003; 90: 593-596.
20. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 5165-5171.